Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma × Prednisolone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Prostatic Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 9 Lymphoma, Follicular 8 Leukemia 8 Lymphoma, Non-Hodgkin 7 Burkitt Lymphoma 5 Hodgkin Disease 4 Neoplasm Metastasis 3 Lymphoma, Large-Cell, Immunoblastic 3 Leukemia, Biphenotypic, Acute 3 Dendritic Cell Sarcoma, Interdigitating 3 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms 2 Multiple Myeloma 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Urogenital Neoplasms 1 Thymoma 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neurotoxicity Syndromes 1 Neoplasms, Plasma Cell 1 Myasthenia Gravis 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell, Marginal Zone 1 Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

Carboplatin 17 Cisplatin 14 Paclitaxel 12 Pemetrexed 11 pembrolizumab 9 Gemcitabine 7 Docetaxel 6 Sorafenib 5 osimertinib 4 durvalumab 4 130-nm albumin-bound paclitaxel 4 padeliporfin 3 cabozantinib 3 atezolizumab 3 Taxes 3 Radiotherapy 3 Mitomycin 3 Magnetic Resonance Spectroscopy 3 Cetuximab 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 trifluridine tipiracil drug combination 2 regorafenib 2 olaparib 2 Sunitinib 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Nivolumab 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00822809 2012-10-03

CASIMAS

Neovii Biotech

Phase 3 Completed

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡